Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)

NCT03852433 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

175

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis Delta

Interventions

DRUG: Bulevirtide
DRUG: Peginterferon Alfa-2a (PEG-IFN alfa)

Sponsor

Gilead Sciences